Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials.
about
Intra-carotid arterial transfusion of autologous circulatory derived CD34+ cells for old ischemic stroke patients - a phase I clinical trial to evaluate safety and tolerabilityNew Advances in the Management of Refractory Angina PectorisLinking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133 cells in ischemic refractory cardiomyopathy trial (RECARDIO)
P2860
Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Autologous CD34+ cell therapy ...... domized double-blinded trials.
@en
Autologous CD34+ cell therapy ...... domized double-blinded trials.
@nl
type
label
Autologous CD34+ cell therapy ...... domized double-blinded trials.
@en
Autologous CD34+ cell therapy ...... domized double-blinded trials.
@nl
prefLabel
Autologous CD34+ cell therapy ...... domized double-blinded trials.
@en
Autologous CD34+ cell therapy ...... domized double-blinded trials.
@nl
P2093
P2860
P356
P1476
Autologous CD34+ cell therapy ...... domized double-blinded trials.
@en
P2093
Andrea S Hunt
Christopher J White
Dean J Kereiakes
Douglas W Losordo
E Marc Jolicoeur
F David Fortuin
Gary L Schaer
Jay H Traverse
Richard A Schatz
Robert Clare
P2860
P356
10.1093/EURHEARTJ/EHX764
P577
2018-01-05T00:00:00Z